1784P Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS
Annals of Oncology（2023）
关键词
prostate-specific cancer,darolutamide,androgen-deprivation androgen-deprivation therapy,low-volume,hormone-sensitive
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要